Fine Control of In Vivo Magnetic Hyperthermia Using Iron Oxide Nanoparticles with Different Coatings and Degree of Aggregation

Cancer; Magnetic hyperthermia; NanoparticlesCáncer; Hipertermia magnética; NanopartículasCàncer; Hipertèrmia magnètica; NanopartículesThe clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target tissue in vivo. Here, forty samples of iron oxide superparamagnetic nanoparticles were prepared by similar methods and thoroughly characterized in terms of size, aggregation degree, and heating response. Selected samples were intratumorally administered in animals with subcutaneous xenografts of human pancreatic cancer. In vivo experiments showed that it is possible to control the rise in temperature by modulating the field intensity during in vivo magnetic hyperthermia protocols. The procedure does not require sophisticated materials and it can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies.This research was funded by European Commission H2020 programme (NoCanTher project, grant agreement no. 685795), the Ministerio de Ciencia e Innovación (PID2019-106301RB-I00), Comunidad de Madrid (Consejería de Educación e Investigación, NANOMAGCOST-CM, ref. P2018/NMT-4321), COST actions MyWave (CA17115) and Nano2Clinic (CA17140). MICINN “Redes de Investigación” (RED2018-102626-T). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, CEX2020-001039-S)

Nanoparticule lipidique de pol ymyxine

The present invention is related to a lipid nanoparticle comprising at least one antibiotic from the polymyxin family, a lipid fraction and one or more surfactants. The invention is also related to the use of the nanoparticle in the prevention and/or treatment of respiratory tree infectionsPeer reviewedBiopraxis Research AlE, Praxis Pharmaceutical, S.A., Fundació d'lnvestigació Sanitaria de Les llles Balears, Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV/EHU), Universidad de Barcelona, Consejo Superior de Investigaciones Científicas (España)B1 Patente sin examen previ

Nanopartícula lipídica de polimixina

La presente invención se relaciona con una nanopartícula lipídica que comprende al menos un antibiótico de la familia de las polimixinas, una composición farmacéutica que comprende dicha nanopartícula y el uso de la nanopartícula en la prevención y/o tratamiento de infecciones del árbol respiratorioPeer reviewedBiopraxis Research AlE, Praxis Pharmaceutical, S.A., Fundació d'lnvestigació Sanitaria de Les llles Balears, Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV/EHU), Universidad de Barcelona, Consejo Superior de Investigaciones Científicas (España)T3 Traducción de patente europe

Lipid nanoparticle of polymyxin

A lipid nanoparticle that includes at least one antibiotic from the polymyxin family, a lipid fraction, and one or more surfactants. The lipid nanoparticle is useful in the prevention and/or treatment of respiratory tree infectionsPeer reviewedBiopraxis Research AlE, Praxis Pharmaceutical, S.A., Fundació d'lnvestigació Sanitaria de Les llles Balears, Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV/EHU), Universidad de Barcelona, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Nanopartícula lipídica de polimixina

[EN] The invention relates to a lipid nanoparticle comprising at least one antibiotic from the polymyxin family, a lipid fraction and one or more surfactants, and to the use of the nanoparticle in the prevention and/or treatment of infections in the respiratory system[ES] La presente invención se relaciona con una nanopartícula lipídica que comprende al menos un antibiótico de la familia de las polimixinas, una fracción lipídica y uno o más tensioactivos,y el uso de la nanopartícula en la prevención y/o tratamiento de infecciones del árbol respiratorio[FR] La présente invention concerne une nanoparticule lipidique qui comprend au moins un antibiotique de la famille des polymyxines, une fraction lipidique et un ou plusieurs tensioactifs, ainsi que l'utilisation de ladite nanoparticule pour la prévention et/ou le traitement d'infections du système respiratoirePeer reviewedBiopraxis Research AlE, Praxis Pharmaceutical, S.A., Fundació d'lnvestigació Sanitaria de Les llles Balears, Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV/EHU), Universidad de Barcelona, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Lipid nanoparticle of polymyxin

A lipid nanoparticle that includes at least one antibiotic from the polymyxin family, a lipid fraction, and one or more surfactants. The lipid nanoparticle is useful in the prevention and/or treatment of respiratory tree infections.Peer reviewedBiopraxis Research AlE, Praxis Pharmaceutical, S.A., Fundació d'lnvestigació Sanitaria de Les llles Balears, Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV/EHU), Universidad de Barcelona, Consejo Superior de Investigaciones Científicas (España)B2 Patente con examen previ

A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS.

The application of nanomaterials in medicine has led to novel pharmaceuticals and medical devices that have demonstrated a strong potential for increasing the efficacy/performance and safety of therapeutic and diagnostic procedures to address a wide range of diseases. However, the successful translation of these technologies from their inception (proof-of-concept) to clinical practice has been challenged by substantial gaps in the scientific and technical capacity of R&D companies, especially SMEs, to keep up with the ever-evolving regulatory expectations in the emerging area of nanomedicine. To address these challenges, the EU Horizon 2020 project REFINE has developed a Decision Support System (DSS) to support developers of nanotechnology-enabled health products in bringing their products to the clinic. The REFINE DSS has been developed to support experts, innovators, and regulators in the implementation of intelligent testing strategies (ITS) for efficient preclinical assessment of nanotechnology-enabled health products. The DSS applies logical rules provided by REFINE experts which generate prioritized lists of assays to be performed (i.e. ITSs) for physicochemical characterisation and for immunotoxicological endpoints. The DSS has been tested against several case studies and was validated by internal project experts as well as external ones.publishedVersio

Lipid nanoparticle of tobramycin

[ES] La presente invención se relaciona con una nanopartícula lipídica que comprende al menos un antibiótico tobramicina, una fracción lipídica y uno o más tensioactivos, y el uso de la nanopartícula en la prevención y/o tratamiento de infecciones del árbol respiratorio.[EN] The invention relates to: a lipid nanoparticle comprising at least one tobramycin antibiotic, a lipid fraction, and one or more surfactants; and the use of the nanoparticle in the prevention and/or treatment of infections of the respiratory tree.Peer reviewedBiopraxis Research AIE, Universidad del Pais Vasco, Universidad de Barcelona, Fundació D'investigació Sanitària De Les Illes Balears, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Nanopartícula lipídica de tobramicina

[EN] The invention relates to: a lipid nanoparticle comprising at least one tobramycin antibiotic, a lipid fraction, and one or more surfactants; and the use of the nanoparticle in the prevention and/or treatment of infections of the respiratory tree.[ES] La presente invención se relaciona con una nanopartícula lipídica que comprende al menos un antibiótico tobramicina, una fracción lipídica y uno o más tensioactivos, y el uso de la nanopartícula en la prevención y/o tratamiento de infecciones del árbol respiratorio.Biopraxis Research AIE, Universidad del Pais Vasco, Universidad de Barcelona, Fundació D'investigació Sanitària De Les Illes Balears, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic